Mirxes（02629.HK）管线重大突破，亚洲结直肠癌将进入“一管血时代”

Core Insights - Mirxes announced a significant breakthrough in its CADENCE-CRC colorectal cancer early screening study, which is the largest prospective blood-based screening trial in Southeast Asia, enrolling over 6,000 participants from diverse ethnic backgrounds [1][3] Group 1: Study Overview - The CADENCE-CRC study is the first large-scale colorectal cancer blood screening trial tailored for the Asian population, with a sample size of 6,000 participants, enhancing the clinical relevance of the results [3][7] - The study has demonstrated a sensitivity of over 80% and specificity of approximately 90% for early colorectal cancer detection, validating the product's performance against the gold standard of colonoscopy [3][7] Group 2: Market Context - The announcement comes in the wake of GRAIL's multi-cancer screening trial failure, which led to a 50% drop in its stock price, indicating a loss of confidence in multi-cancer screening concepts [1] - In contrast, Mirxes focuses on single-cancer screening, which may present a more reliable investment opportunity amid rising market risk aversion [1] Group 3: Product Launch Strategy - Mirxes plans to launch the colorectal cancer screening product in LDT format in Singapore and select Southeast Asian markets by mid-2026, with an IVD registration application expected by the end of the year [1][5] - The product pipeline includes gastric cancer and lung cancer screening, with the gastric cancer product already registered in China and expected to provide stable cash flow for further development [4][5] Group 4: Capital Stability - The company benefits from a stable capital environment, with early investors facing high holding costs, reducing the likelihood of significant sell-offs that could impact product commercialization [6] - The high cost of shares held by cornerstone investors ensures that there is minimal market pressure, allowing the company to focus on product launch and market penetration [6] Group 5: Addressing Market Needs - The introduction of a locally developed, non-invasive colorectal cancer screening product addresses the long-standing gap in the Asian market, which has been dominated by Western-developed products that may not suit local genetic and screening needs [7] - The product's design and clinical validation are expected to enhance screening participation rates, ultimately contributing to a reduction in colorectal cancer mortality in Asia [7]